Anavex appoints new SAB member
This article was originally published in Scrip
Anavex Life Sciences, a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types of cancer, has appointment of Dr Jacqueline French to its scientific advisory board. Dr French is an award-winning, internationally recognized expert on epilepsy, new therapeutic interventions and clinical trial methodology. She co-directs a bi-annual symposium on trial design and its implications and holds positions on committees of the American Academy of Neurology (AAN), where she has also co-authored several AAN clinical practice guidelines.